CEDAR KNOLLS, N.J.,
March 31, 2017 /PRNewswire/ --
Interested parties may access the call as
follows:
Event
Title: Management Highlights
Event Date: 4/4/17
Event Time: 11:00 AM EDT
|
Live
Participant
Dial-In:
US &
Canada:
877-407-8309
International:
201-689-8057
|
Webcast
URL:
http://myosrens.equisolvewebcast.com/4-4-17
|
MYOS RENS Technology Inc. ("MYOS" or the "Company")
(NASDAQ: MYOS), a biotherapeutics and bionutrition company focused
on developing products that build muscle and improve muscle health
and performance, will file its Annual Report on Form 10-K for the
year ended December 31, 2016 (the
"Form 10-K") with the Securities and Exchange Commission on
Friday, March 31, 2017. The Form 10-K
will be accessible via the 'SEC Filings' page of the Investor
Relations section of the Company's corporate web site at
www.myosrens.com on that date.
Moderated by CEO Joseph Mannello,
the call will focus on the launch of the Qurr product line
(Qurr.com), and will highlight significant developments of the last
seven months. Participants will have the opportunity to ask
questions or comment following the presentation.
About MYOS RENS Technology Inc.
MYOS RENS Technology
(MYOS), "The Muscle Company™", is a Cedar
Knolls, NJ-based biotherapeutics and bionutrition company
focused on developing products that improve muscle health and
performance and brings them to market. MYOS is the owner of
Fortetropin®, the world's first clinically demonstrated myostatin
reducer (myostatin is a natural regulatory protein, which inhibits
muscle growth). Fortetropin® is manufactured through a proprietary
process which retains its biological activity. MYOS believes
that Fortetropin® has the potential to redefine existing standards
of physical health and wellness enhancement. For more information
on MYOS and its proprietary ingredient, Fortetropin®, visit
www.myosrens.com.
About Qurr
The Qurr product series is the Company's
newly-branded line of muscle health products. These
all-natural, non-GMO products contain Fortetropin®, an egg-based,
all natural myostatin reducer clinically proven to build healthy
muscle. Qurr products can be ordered by visiting www.qurr.com. The
Qurr product line is owned and sold directly by the Company through
Qurr.com and Amazon.com.
Forward-Looking Statements
Any statements in this
release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful launch of our
products, including Qurr products, the success of our research and
development, the results of the clinical evaluation of Fortetropin®
and its effects, the ability to enter into partnership
opportunities, the ability to generate the forecasted revenue
stream and cash flow from sales of our products, the ability to
achieve a sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure, or prevent any disease.
MYOS Corporation Investor and Media Contact:
MYOS Corporation
Joanne Goodford
(973) 509-0444
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/myos-rens-technology-to-host-april-4-interactive-conference-call-on-qurr-product-launch-300432373.html
SOURCE MYOS RENS Technology